IP Library Granted Patent US 11,931,478
Granted Patent B2
US 11,931,478 · App. 16/609,772 · Granted Mar 19, 2024

Post-3D printing functionalization of polymer scaffolds for enhanced bioactivity

Inventors: Matthew Becker (Chapel Hill, NC); Yanyi Xu (Cuyahoga Falls, OH)
Assignee: The University of Akron
A61L27/18A61L27/3808A61L27/3821A61L27/3834A61L27/44A61L27/54A61L27/56A61L27/58A61L2300/25A61L2300/252A61L2300/404A61L2300/412A61L2300/414A61L2430/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,931,478
App. No.
16/609,772
Granted
Mar 19, 2024
Kind
B2
Abstract

In various aspects, the present invention is directed to novel bioactive peptide loaded poly(propylene fumarate) (PPF) tissue scaffolds and related methods for their making and use. In various embodiments, these bioactive peptide loaded poly(propylene fumarate) tissue scaffolds are formed by forming a PPF structure or matrix using photochemical 3-D printing techniques and then loading that printed PPF structure or matrix with a bioactive peptides or other bioactive compounds that have, or have been functionalized to have, a thiol functional group at or near its terminus. The thiol groups on the bioactive peptides or other compound will react with exposed alkene functional groups on the PPF polymer matrix via a thiol-ene “click” reaction, thereby binding these bioactive peptides or other compounds to the tissue scaffolds. The bioactive peptide loaded PPF tissue scaffolds of the present invention are particularly useful in repairing bone defects.

Claims (18)

1. A method of making a bioactive compound loaded poly(propylene fumarate) tissue scaffold comprising:

a. preparing a 3-D printable resin comprising a poly(propylene fumarate) polymer having alkene functional groups in its polymer chain;

b. forming a poly(propylene fumarate) polymer structure from said 3-D printable resin using 3-D printing technology, wherein said poly(propylene fumarate) polymer structure has a surface with exposed alkene functional groups;

c. preparing a bioactive compound having at least one thiol functional group at or near its terminus selected from the group consisting of basic fibroblast growth factor (bFGF) (CYKRSRYT (SEQ. ID NO. 1)), Bone Morphogenetic Protein 2 (BMP-2) (CKIPKASSVPTELSAISTLYL (SEQ. ID NO. 2), Osteogenic Growth Peptide (OGP), 10-14 (YGFGG) (SEQ. ID NO. 3), BMP-2 73-92 (KIPKASSVPTELSAISTLYL) (SEQ. ID NO. 4), BMP-7 89-117 (TVPKPSSAPTQLNAISTLYF) (SEQ. ID NO. 5), BMP-9 68-87 (KVGKASSVPTKLSPISILYK) (SEQ. ID NO. 6), and combinations thereof;

d. contacting said poly(propylene fumarate) polymer structure with said bioactive compound; wherein the least one thiol functional group on said bioactive compound reacts with the alkene functional groups in the poly(propylene fumarate) polymer chains exposed on the surface of said poly(propylene fumarate) polymer structure, thereby tethering said bioactive compound to said poly(propylene fumarate) polymer structure to form a bioactive compound loaded tissue scaffold.

2. The method of claim 1 wherein said 3-D printable resin further comprises diethyl fumarate (DEF).

3. The method of claim 1 wherein said 3-D printable resin further comprises at least one of photoinitiators, dyes, light attenuating agents, dispersants, emulsifiers, ceramics, bioglass, hydroxyapatite, β-tricalcium phosphate, and solvents.

4. The method of claim 1 wherein said poly(propylene fumarate) polymer has a number average molecular weight (M n ) as measured by size exclusion chromatography or mass spectroscopy of from about 500 g/mole to about 10,000 g/mole.

5. The method of claim 1 wherein said poly(propylene fumarate) polymer has a polydispersity index (Ð m ) as measured by size exclusion chromatography of from about 1.0 to about 2.0.

6. The method of claim 1 wherein the poly(propylene fumarate) polymer structure formed in said step of forming (step B) is porous.

7. The method of claim 1 further comprising:

E. seeding the tissue scaffold with cells; and

F. growing said cells on said tissue scaffold.

8. The method of claim 7 wherein said cells are selected from the group consisting of endothelial cells, osteocytes, mesenchymal stem cells, osteoblasts, and combinations thereof.

9. The method of claim 1 wherein said poly(propylene fumarate) polymer has a number average molecular weight (M n ) as measured by size exclusion chromatography or mass spectroscopy of from 1000 g/mole to 5000 g/mole.

10. The method of claim 1 wherein said poly(propylene fumarate) polymer has a number average molecular weight (M n ) as measured by size exclusion chromatography or mass spectroscopy of from 1000 g/mole to 3000 g/mole.

11. The method of claim 1 wherein said poly(propylene fumarate) polymer has a polydispersity index (Ð m ) as measured by size exclusion chromatography of from about 1.05 to about 1.6.

12. The method of claim 1 wherein said poly(propylene fumarate) polymer has a polydispersity index (Ð m ) as measured by size exclusion chromatography of from about 1.05 to about 1.2.

Assignments (1)
CONFIRMATORY LICENSE Recorded Apr 4, 2025
From: UNIVERSITY OF AKRON
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 070741/0014 →
Continuity (2)
Provisional Application 62500777 · May 3, 2017
Related Publication 20200230286A1 · Jul 23, 2020